Immunomedics is classified as operating in the Scientific Research & Development Services industry, NAICS Code 5417.
Immunomedics is a publicly traded company on NGM using the ticker symbol IMMU.
Detailed information on company financials and operating reports can be found here:
NGM: IMMU
Note: Immunomedics's revenues are gauged from an analysis of company filings.
Trademark Applications
Trademark applications show the products and services that Immunomedics is developing and marketing.
Immunomedics doesn't have any recent trademark applications, indicating Immunomedics is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
Trademark
Date
TRODELVY Pharmaceutical preparations for the treatment of oncological disorders, inflammatory disorders
06/09/2021
HUMANLY Educational services, namely, providing ongoing information to patients and healthcare providers regarding cancer care, cancer treatments, cancer diagnosis via workshops, conferences and online training
07/19/2018
See all trademarks and details in the Full Report.
Market Share of Immunomedics's Largest Competitors
A competitive analysis shows these companies are in the same general field as Immunomedics, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Immunomedics.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Immunomedics and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.